ID: ALA5269298

Max Phase: Preclinical

Molecular Formula: C20H18Cl2N4O

Molecular Weight: 401.30

Associated Items:

Representations

Canonical SMILES:  O=C(Cc1ccc(Cl)c(Cl)c1)N1CCN(c2cc3ccncc3cn2)CC1

Standard InChI:  InChI=1S/C20H18Cl2N4O/c21-17-2-1-14(9-18(17)22)10-20(27)26-7-5-25(6-8-26)19-11-15-3-4-23-12-16(15)13-24-19/h1-4,9,11-13H,5-8,10H2

Standard InChI Key:  OMTYWHCWOSONTE-UHFFFAOYSA-N

Associated Targets(non-human)

Cryptosporidium parvum 1150 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 401.30Molecular Weight (Monoisotopic): 400.0858AlogP: 3.83#Rotatable Bonds: 3
Polar Surface Area: 49.33Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 4.37CX LogP: 3.35CX LogD: 3.35
Aromatic Rings: 3Heavy Atoms: 27QED Weighted: 0.67Np Likeness Score: -1.59

References

1. Oboh E, Teixeira JE, Schubert TJ, Maribona AS, Denman BN, Patel R, Huston CD, Meyers MJ..  (2023)  Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.,  86  [PMID:37148788] [10.1016/j.bmc.2023.117295]

Source